Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Saved in:
Bibliographic Details
Title: Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Authors: Perkovic V; University of New South Wales, Sydney., Trimarchi H; Hospital Británico, Buenos Aires., Tesar V; Charles University, Prague, Czech Republic., Lafayette R; Stanford University Medical Center, Stanford, CA., Wong MG; Concord Repatriation General Hospital, Concord, NSW, Australia., Barratt J; University of Leicester, Leicester, United Kingdom., Suzuki Y; Juntendo University Faculty of Medicine, Tokyo., Liew A; Mount Elizabeth Novena Hospital, Singapore., Zhang H; Peking University First Hospital, Beijing., Carroll K; KJC Statistics, Cheadle, United Kingdom., Jha V; George Institute for Global Health, UNSW, New Delhi, India.; School of Public Health, Imperial College London, London.; Manipal Academy of Higher Education, Manipal, India., Quevedo A; Investigación Clinica Aplicada SRL, Buenos Aires., Han SH; Yonsei University College of Medicine, Seoul, South Korea., Praga M; Department of Medicine, Complutense University, Madrid., Chacko B; Nephrology and Transplantation, John Hunter Hospital and University of Newcastle, Newcastle, NSW, Australia., Sahay M; Osmania General Hospital, Hyderabad, India., Cheung CK; University of Leicester, Leicester, United Kingdom., Kooienga L; Colorado Kidney Care, Denver., Walsh M; Department of Medicine, McMaster University, Hamilton, ON, Canada.; Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada., Xia J; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Fajardo C; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Shah L; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Hafkin J; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Rizk DV; Division of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham.
Corporate Authors: VISIONARY Trial Investigators Group
Source: The New England journal of medicine [N Engl J Med] 2026 Feb 12; Vol. 394 (7), pp. 635-646. Date of Electronic Publication: 2025 Nov 08.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1533-4406
DOI:10.1056/NEJMoa2512133